STAAR Surgical Projects Q1 Net Sales Over $90M, Signaling Strong Rebound and Profit Improvement

summarizeSummary

STAAR Surgical announced preliminary Q1 2026 net sales are expected to exceed $90 million, more than doubling Q1 2025 sales and indicating a significant operational turnaround after a challenging prior year.

check_boxKey Events

• Preliminary Q1 2026 Net Sales Exceed Expectations

  The company expects net sales for the first quarter of 2026 to be over $90 million, a substantial increase from $42.6 million in Q1 2025.

• Significant Operational Turnaround

  This strong performance, driven by growth in China and the Americas, follows a challenging fiscal year 2025 which saw a 23.7% sales drop and a widened net loss.

• Expected Profitability Improvement

  Higher net sales combined with an improved cost structure are anticipated to lead to a meaningful improvement in adjusted EBITDA for the quarter.

• Addresses Strategic Objectives

  These results deliver on the company's core objectives of 'Revenue Growth and Profit Expansion' outlined earlier this year.

auto_awesomeAnalysis

STAAR Surgical's preliminary Q1 2026 net sales exceeding $90 million represents a significant operational turnaround, more than doubling the $42.6 million reported in Q1 2025. This positive development follows a challenging fiscal year 2025, which saw a substantial 23.7% drop in net sales and a widened net loss, alongside a terminated merger agreement and leadership changes. The strong performance, primarily driven by growth in China and the Americas, is expected to lead to a meaningful improvement in adjusted EBITDA, addressing key strategic objectives of revenue growth and profit expansion. While the company notes volatile global conditions and declines in some EMEA and APAC regions, the overall preliminary results indicate a robust recovery from previous difficulties.